Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart

Techbio company Qureight has announced the close of their significantly oversubscribed €8 million Series A round. Hargreave Hale AIM VCT led the round, joined ... Read more

Bron:

EU-startups.com